Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:1118-1119 (13 November), doi:10.1136/bmj.329.7475.1118
We need to scale up its use and reach with existing facilities in poor countries
| The first 150 words of the full text of this article appear below. |
The barriers to providing highly active antiretroviral therapy (HAART) in poor countries have until recently seemed insurmountable. The cited problems have ranged from weak health systems and poor infrastructure to inadequate numbers of health professionals. In reality, the main barrier has been the very high cost of antiretroviral drugs. Current increase in access to HAART has resulted from cuts in the price of antiretroviral drugs and increased funding by international bodies, notably the Global AIDS Fund, the World Bank, and the President Bush Emergency Program for AIDS Relief.
Africa's grim AIDS data include 25 million people living with HIV and 2.2 million dead in 2003 alone.1 The challenge now is to move quickly from small town or community specific projects to provide nationwide high quality, equitable, and sustainable programmes. Valuable lessons have been learned from pilot programmes in poor countries, including the Malawi experience described in this issue, but
Peter Mugyenyi, director
Joint Clinical Research Centre, 1 Ring Road, Mengo, PO Box 10005, Kampala, Uganda (pmugyenyi@yahoo.co.uk)
Read all Rapid Responses